New-generation tyrosine kinase inhibitor-associated asymptomatic cerebrovascular stenosis: two illustrative cases

Acta Neurochir (Wien). 2022 Jun;164(6):1623-1626. doi: 10.1007/s00701-021-05043-3. Epub 2021 Nov 26.

Abstract

New-generation tyrosine kinase inhibitors (TKIs), nilotinib and ponatinib, for chronic myelogenous leukemia (CML) have been reported to cause symptomatic cerebral ischemia. Herein, we report two patients with asymptomatic cerebral artery stenosis associated with these TKIs, as a previously unreported finding. Both patients were in their 40 s and administered new-generation TKIs without vascular risk factors. New-generation TKIs for CML can cause major cerebrovascular stenosis without any symptoms. Examining the neck and intracranial arteries using magnetic resonance angiography and carotid ultrasonography may prevent future cerebral infarctions associated with these TKIs.

Keywords: Asymptomatic lesion; Cerebral infarction; Cerebrovascular stenosis; Tyrosine kinase inhibitor.

MeSH terms

  • Constriction, Pathologic
  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / chemically induced
  • Protein Kinase Inhibitors* / adverse effects

Substances

  • Protein Kinase Inhibitors